WO2008152015A1 - Composition destinée à atténuer les difficultés fonctionnelles liées aux affections du cartilage articulaire - Google Patents
Composition destinée à atténuer les difficultés fonctionnelles liées aux affections du cartilage articulaire Download PDFInfo
- Publication number
- WO2008152015A1 WO2008152015A1 PCT/EP2008/057151 EP2008057151W WO2008152015A1 WO 2008152015 A1 WO2008152015 A1 WO 2008152015A1 EP 2008057151 W EP2008057151 W EP 2008057151W WO 2008152015 A1 WO2008152015 A1 WO 2008152015A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- functional
- oral administration
- weight
- composition according
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 70
- 206010061762 Chondropathy Diseases 0.000 title claims abstract description 17
- 208000024429 articular cartilage disease Diseases 0.000 title claims abstract description 17
- 230000006872 improvement Effects 0.000 title claims abstract description 17
- 102000008186 Collagen Human genes 0.000 claims abstract description 32
- 108010035532 Collagen Proteins 0.000 claims abstract description 32
- 229920001436 collagen Polymers 0.000 claims abstract description 32
- 239000000413 hydrolysate Substances 0.000 claims abstract description 26
- 230000002255 enzymatic effect Effects 0.000 claims abstract description 25
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 25
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 24
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 23
- 229940093797 bioflavonoids Drugs 0.000 claims abstract description 20
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 20
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 17
- 235000013376 functional food Nutrition 0.000 claims abstract description 17
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- 241000124008 Mammalia Species 0.000 claims abstract description 11
- 229920000642 polymer Polymers 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 239000002253 acid Substances 0.000 claims abstract description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 36
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 14
- 229930003268 Vitamin C Natural products 0.000 claims description 14
- 235000006708 antioxidants Nutrition 0.000 claims description 14
- 235000019154 vitamin C Nutrition 0.000 claims description 14
- 239000011718 vitamin C Substances 0.000 claims description 14
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 12
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 10
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 10
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 10
- 235000012661 lycopene Nutrition 0.000 claims description 10
- 239000001751 lycopene Substances 0.000 claims description 10
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 10
- 229960004999 lycopene Drugs 0.000 claims description 10
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 9
- 239000001913 cellulose Substances 0.000 claims description 9
- 229920002678 cellulose Polymers 0.000 claims description 9
- 229940088594 vitamin Drugs 0.000 claims description 9
- 229930003231 vitamin Natural products 0.000 claims description 9
- 235000013343 vitamin Nutrition 0.000 claims description 9
- 239000011782 vitamin Substances 0.000 claims description 9
- CVCQAQVBOPNTFI-AAONGDSNSA-N (3r,4r,5s,6r)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol;sulfuric acid Chemical compound OS(O)(=O)=O.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O CVCQAQVBOPNTFI-AAONGDSNSA-N 0.000 claims description 8
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 7
- 239000011707 mineral Substances 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 6
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 6
- 230000009471 action Effects 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 235000005875 quercetin Nutrition 0.000 claims description 6
- 229960001285 quercetin Drugs 0.000 claims description 6
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 5
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 5
- 239000012736 aqueous medium Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 150000001719 carbohydrate derivatives Chemical class 0.000 claims description 5
- 235000021283 resveratrol Nutrition 0.000 claims description 5
- 229940016667 resveratrol Drugs 0.000 claims description 5
- 235000013618 yogurt Nutrition 0.000 claims description 5
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 claims description 4
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 4
- 235000008714 apigenin Nutrition 0.000 claims description 4
- 229940117893 apigenin Drugs 0.000 claims description 4
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 claims description 4
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 claims description 4
- 235000010323 ascorbic acid Nutrition 0.000 claims description 4
- 239000011668 ascorbic acid Substances 0.000 claims description 4
- 229960005070 ascorbic acid Drugs 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 235000006539 genistein Nutrition 0.000 claims description 4
- 229940045109 genistein Drugs 0.000 claims description 4
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims description 4
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims description 4
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 claims description 4
- 235000009498 luteolin Nutrition 0.000 claims description 4
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 claims description 4
- 229940052490 naringin Drugs 0.000 claims description 4
- 229930019673 naringin Natural products 0.000 claims description 4
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 claims description 4
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims description 3
- 241000282472 Canis lupus familiaris Species 0.000 claims description 3
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 3
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims description 3
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 3
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 claims description 3
- 235000013734 beta-carotene Nutrition 0.000 claims description 3
- 239000011648 beta-carotene Substances 0.000 claims description 3
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 3
- 229960002747 betacarotene Drugs 0.000 claims description 3
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 claims description 3
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 3
- 229940110767 coenzyme Q10 Drugs 0.000 claims description 3
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 3
- 235000011950 custard Nutrition 0.000 claims description 3
- 229940025878 hesperidin Drugs 0.000 claims description 3
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims description 3
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 claims description 3
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 claims description 3
- 159000000000 sodium salts Chemical class 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 3
- 241000283086 Equidae Species 0.000 claims description 2
- 241000282326 Felis catus Species 0.000 claims description 2
- 235000015895 biscuits Nutrition 0.000 claims description 2
- 239000005515 coenzyme Substances 0.000 claims description 2
- 235000015203 fruit juice Nutrition 0.000 claims description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 abstract description 7
- 239000001257 hydrogen Substances 0.000 abstract description 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 4
- 239000003531 protein hydrolysate Substances 0.000 abstract description 4
- 239000000047 product Substances 0.000 description 18
- 238000011282 treatment Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 8
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 7
- 240000003768 Solanum lycopersicum Species 0.000 description 7
- 229920000159 gelatin Polymers 0.000 description 7
- 235000019322 gelatine Nutrition 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000001828 Gelatine Substances 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 235000010755 mineral Nutrition 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 5
- 229930091371 Fructose Natural products 0.000 description 4
- 239000005715 Fructose Substances 0.000 description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 4
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229960004543 anhydrous citric acid Drugs 0.000 description 4
- 210000000845 cartilage Anatomy 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 201000008482 osteoarthritis Diseases 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 3
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 3
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 3
- 108010059892 Cellulase Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 3
- 239000005913 Maltodextrin Substances 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 239000000619 acesulfame-K Substances 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 239000002518 antifoaming agent Substances 0.000 description 3
- 210000001188 articular cartilage Anatomy 0.000 description 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 3
- 229940106157 cellulase Drugs 0.000 description 3
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 229960002442 glucosamine Drugs 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 229940035034 maltodextrin Drugs 0.000 description 3
- 235000010241 potassium sorbate Nutrition 0.000 description 3
- 239000004302 potassium sorbate Substances 0.000 description 3
- 229940069338 potassium sorbate Drugs 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- 235000016623 Fragaria vesca Nutrition 0.000 description 2
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 235000011034 Rubus glaucus Nutrition 0.000 description 2
- 244000235659 Rubus idaeus Species 0.000 description 2
- 235000009122 Rubus idaeus Nutrition 0.000 description 2
- 235000021028 berry Nutrition 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 2
- 229960002079 calcium pantothenate Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- 239000008371 vanilla flavor Substances 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 235000009492 vitamin B5 Nutrition 0.000 description 2
- 239000011675 vitamin B5 Substances 0.000 description 2
- 235000019158 vitamin B6 Nutrition 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 230000007730 Akt signaling Effects 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical class [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010073767 Developmental hip dysplasia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 244000307700 Fragaria vesca Species 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000007446 Hip Dislocation Diseases 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical class [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical class [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003571 Vitamin B5 Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 235000004584 Yucca mohavensis Nutrition 0.000 description 1
- 244000110633 Yucca schidigera Species 0.000 description 1
- 235000006012 Yucca schidigera Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical class [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000010398 acute inflammatory response Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002225 anti-radical effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010376 calcium ascorbate Nutrition 0.000 description 1
- 229940047036 calcium ascorbate Drugs 0.000 description 1
- 239000011692 calcium ascorbate Substances 0.000 description 1
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 208000015100 cartilage disease Diseases 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012085 chronic inflammatory response Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Chemical class 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 235000021185 dessert Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Chemical class 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Chemical class 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000017128 negative regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000011591 potassium Chemical class 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011669 selenium Chemical class 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011734 sodium Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- -1 sterol esters Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000003845 vascular endothelial function Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000011701 zinc Chemical class 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
- A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
- A21D2/14—Organic oxygen compounds
- A21D2/145—Acids, anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
- A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
- A21D2/24—Organic nitrogen compounds
- A21D2/26—Proteins
- A21D2/261—Animal proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1322—Inorganic compounds; Minerals, including organic salts thereof, oligo-elements; Amino-acids, peptides, protein-hydrolysates or derivatives; Nucleic acids or derivatives; Yeast extract or autolysate; Vitamins; Antibiotics; Bacteriocins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/154—Milk preparations; Milk powder or milk powder preparations containing additives containing thickening substances, eggs or cereal preparations; Milk gels
- A23C9/1544—Non-acidified gels, e.g. custards, creams, desserts, puddings, shakes or foams, containing eggs or thickening or gelling agents other than sugar; Milk products containing natural or microbial polysaccharides, e.g. cellulose or cellulose derivatives; Milk products containing nutrient fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/20—Feeding-stuffs specially adapted for particular animals for horses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/40—Shaping or working of foodstuffs characterised by the products free-flowing powder or instant powder, i.e. powder which is reconstituted rapidly when liquid is added
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a composition comprising polymers of protein origin or cellulose, acrylic or carbohydrate derivatives for the improvement of functional difficulties which are a result of articular cartilage disorders.
- the present invention relates to uses of the mentioned composition and to functional foods and food supplements comprising it.
- gelatine hydrolysates are also useful as coadjuvants in the treatments intended to compensate the calcium deficit and that they are also useful in the treatment and prevention of hip dysplasia in dogs as described in patent document ES2104507.
- the inventors of the present invention developed a high-purity enzymatic collagen hydrolysate with a better bioavailability due to its lower molecular weight (between 5000 and 20000 daltons).
- This hydrolysate is distributed under the trade name Colatech® and a study was conducted with it in 100 healthy volunteers, this collagen being administered in a dose of 10 g per day to 50 of them and to the other 50 volunteers a dose of 1 .5 g per day of glucosamine sulphate, a product widely used both in Europe and in the United States at this dose for the treatment of articular disorders in general.
- antioxidants such as lycopene obtained from tomato, resveratrol which can be obtained from Yucca schidigera and even vitamin C are being used as natural anti-inflammatory agents (Riso P, Visioli F, Grande S, Guarneri S, Gardana C, Simonetti P, Porrini M. Effect of a tomato-based drink on markers of inflammation, immunomodulation, and oxidative stress, J. Agric Food Chem. 2006 Apr 5; 54 (7): 2563-6; Liu X, Qu D, he F, Lu Q, Wang J, Cai D. Effect of Lycopene on the vascular endothelial function and expression of inflammatory agents in hyperhomocysteinemic rats, Asia Pac J Clin Nutr.
- Natural bioflavonoids such as luteolin, naringin, quercetin, apigenin and genistein are also being widely used in dietary or food supplements due to their antiinflammatory action allowing their application in different disorders presenting inflammation (Nam N. H., Naturally occurring NF-kappaB inhibitors, Mini Rev. Med. Chem. 2006 Aug; 6 (8):945-51 ; Kumazawa Y. Kawaguchi K. Takimoto H., lmmunomodulating effects of flavonoids on acute and chronic inflammatory responses caused by tumor necrosis factor alpha, Curr. Pharm. Des. 2006,12 (32); 4271 -9; Ruiz P. A.
- Haller D. Functional diversity of flavonoids in the inhibition of the proinflammatory NF-kappaB, IRF, and Akt signaling pathways in murine intestinal epithelial cells, J. Nutr. 2006 Mar;136 (3); 664-71 ; Ruiz PA, Braune A, Holziwimmer G, Quintanilla - Fend L, Haller D., Quercetin inhibits TNF-induced NF-kappaB transcription factor recruitment to proinflammatory gene promoters in murine intestinal epithelial cells, J.Nutr. 2007 May; 137 (5); 1208 - 15).
- Collagen has also been used in the field of food supplements to obtain preparations favouring the recovery of cartilage in animals suffering from diseases linked to this type of tissue.
- a food supplement must be understood as any additional dietary intake which is consumed orally and contains a "food ingredient" intended to supplement the diet.
- Some examples of dietary or food supplements are vitamins, minerals, herbs (a single herb or a mixture of several herbs), other botanical products, amino acids and food components such as enzymes.
- Food supplements are generally distributed in the form of different presentations such as pastilles, capsules, soft gelatine capsules, gelatine capsules, liquids and powders.
- Functional foods are nowadays also becoming known in the nutrition field. Functional foods are considered to be those foods which are consumed as part of a normal diet and contain biologically active components offering health benefits and reducing the risk of suffering from diseases. Foods containing certain minerals, vitamins, fatty acids or dietary fibre, foods to which biologically active substances such as phytochemicals or other antioxidants have been added, and probiotics, having live cultures of beneficial microorganisms, are emphasized among some examples of functional foods. Some yoghurts with probiotics, some margarines enriched with sterol esters and eggs rich in omega-3-type fatty acids are examples of functional foods.
- hyaluronic acid When hyaluronic acid is associated with a polymer of protein origin or cellulose, acrylic or carbohydrate derivatives, hydrogen bonds are formed between the structure of the polymer, for example, of the collagen hydrolysate (amino and hydroxyl groups capable of forming this type of bond) and the hyaluronic acid molecule, favouring the passage of the latter through cell membranes and subsequently improving its absorption and causing an improvement in its activity.
- collagen hydrolysate amino and hydroxyl groups capable of forming this type of bond
- the polymer is a cellulose derivative, being an enzymatic collagen hydrolysate.
- the composition for oral administration according to the invention is characterized in that it can further comprise other functional ingredients such as natural bioflavonoids and antioxidants.
- the enzymatic collagen hydrolysate preferably has a molecular weight comprised between 1 ,000 and 50,000 daltons.
- the composition for oral administration comprises from 96% to 99.5% by weight of enzymatic collagen hydrolysate, from 0.25% to 0.60% by weight of hyaluronic acid, from 1.0% to 2.5% of antioxidant agents and/or from 0.40% to 0.90% by weight of natural bioflavonoids being able to be incorporated to this association.
- the natural bioflavonoids are chosen from the group consisting of quercetin, naringin, luteolin, apigenin, genistein, hesperidin or a mixture of at least two of them.
- hyaluronic acid is in the form of sodium salt.
- the composition comprises as an antioxidant at least one of those of the group consisting of beta-carotene, lycopene, resveratrol as well as their derivatives.
- resveratrol refers to its cis and trans isomers and to mixtures thereof, as well to its derivatives by glycosylation of its hydroxyl groups; esterification of said hydroxyl groups or amides thereof in any of its isomeric forms.
- the composition further comprises vitamin C, which will preferably be in the form of ascorbic acid.
- composition for oral administration object of the invention further comprises mineral salts.
- composition for oral administration further comprises B group vitamins and/or coenzymes, liposoluble vitamins and coenzyme Q10.
- composition for oral administration according to the invention is also characterized in that it further comprises a coadjuvant compound selected from the group consisting of glucosamine sulphate and chondroitin sulphate.
- composition for oral administration according to the invention is characterized in that it is in the form of a suspension.
- composition for oral administration according to the invention is characterized in that it is in the form of a powder which is dispersible or soluble in an aqueous medium.
- composition for oral administration according to the invention is also characterized in that it is in the form of a solution.
- composition for oral administration according to the invention which is in the form of tablets or capsules is equally preferred.
- Another object of the present invention is a functional food comprising a composition with polymers of protein origin or cellulose, acrylic or carbohydrate derivatives associated with natural bioflavonoids, antioxidants and hyaluronic acid in the form of acid or of their salts, as has been described above.
- the functional food is preferably in the form of yoghurt, shake, custards, fruit juices, biscuits or energy bars.
- Another object of the present invention is the use of the previously described compositions for the preparation of functional foods and food supplements for the improvement of the functional capacity and/or the quality of life of a mammal with functional difficulties derived from articular cartilage disorders.
- the daily dose of the enzymatic collagen hydrolysate is comprised between 0.075 and 0.200 g per Kg of weight
- the daily dose of bioflavonoids is comprised between 0.00025 and 0.001 g per Kg of weight
- the daily dose of hyaluronic acid is comprised between 0.0001 and 0.001 g per Kg of weight
- the daily dose of antioxidants is comprised between 0.00075 and 0.003 mg per Kg of weight.
- the composition comprises vitamin C in a dose comprised between 0.0005 and 0.002 g per Kg of weight.
- the use according to the invention is characterized in that the mammal with functional difficulties derived from articular cartilage disorders is a human.
- the mammal with functional difficulties derived from articular cartilage disorders is an animal selected from the group consisting of dogs, cats and horses.
- compositions object of the invention are effective due to the synergistic behaviour of their constituents
- compositions and use examples thereof are detailed below by way of a non-limiting example. Tests which allow viewing the positive effects of these new compositions are also set forth.
- TEST Comparison between compositions according to the invention and compositions according to the state of the art to determine their efficacy as products for the improvement of the functional capacity and/or the quality of life in mammals with difficulties derived from articular cartilage disorders.
- a composition according to the invention and as detailed below was designed with the intention of reducing the daily dose of enzymatic collagen hydrolysate to be administered compared to the preparations existing on the market.
- a typical dose of 10 grams a day was thus reduced to 7 grams, and hyaluronic acid, natural bioflavonoids and natural antioxidants were added to it in the average doses used of these products individually, the composition for the daily dose of said product being as follows:
- Enzymatic collagen hydrolysate (Colatech®) 7.000 g
- Hyaluronic acid 0.025 g Tomato extract with 2% Lycopene 0.075 g
- the enzymatic collagen hydrolysate used has a high purity, i.e., it comprises 99% by weight of hydrolysate of the dry raw material product. Likewise, the molecular weight of said enzymatic collagen hydrolysate is comprised between
- composition As a base, a suspension was prepared which was stabilized with different pharmaceutical quality excipients and it was suitably flavoured for the purpose of facilitating the consumption thereof.
- EXAMPLE 1 Functional food in the form of yoghurt.
- Enzymatic collagen hydrolysate (Colatech®) 7.000 g
- Tomato concentrate with 2% Lycopene 0.075 g Vitamin C 0.060 g
- Skimmed milk powder 12.000 g
- a chocolate dessert with the following composition has been prepared:
- Enzymatic collagen hydrolysate (Colatech®) 7.000 g
- Tomato concentrate with 2% Lycopene 0.075 g Vitamin C 0.060 g
- Pregelatinized corn starch 10.000 g Carrageenan 4.000 g
- EXAMPLE 3 Food supplement in the form of a vial that is drinkable or can be diluted in aqueous medium and with raspberry flavour.
- liquid presentation indicated below has been prepared to be taken in 30 g vials, either directly or diluted in water.
- Enzymatic collagen hydrolysate (Colatech®) 23.334 g
- Tomato concentrate with 2% Lycopene 0.250 g Vitamin C 0.200 g
- Antifoam AF 0.040 g Colloidal silicon dioxide 0.02O g
- EXAMPLE 4 Food supplement in the form of a powder and with strawberry flavour.
- a mixture of powders has been prepared which can be packaged in jars adding a measuring device allowing the dosing of about 12 g in order to take the product once it has been dispersed in half a glass of water. It can also be packaged in single-dose paper-aluminium-polythene sachets whereby carrying the daily dose to be taken is favoured.
- Enzymatic collagen hydrolysate (Colatech®) 58.344 g
- Hyaluronic acid 0.208 g
- Natural bioflavonoids 0.25O g
- Vitamin C 0.50O g
- Vitamin B1 Thiamine HCI 0.02O g
- Vitamin B2 Raboflavin 0.02O g
- Vitamin B6 (Pyridoxine HCI) 0.020 g
- Vitamin B5 (Calcium pantothenate) 0.06O g
- EXAMPLE 5 Food supplement in the form of a vial that is drinkable or can be diluted in aqueous medium and with vanilla flavour.
- the liquid presentation indicated below has been prepared to be taken in 30 g vials, either directly or diluted in water.
- EXAMPLE 6 Food supplement in the form of a vial that is drinkable or can be diluted in aqueous medium and with wild berry flavour.
- compositions for oral administration comprising an enzymatic collagen hydrolysate or other types of polymer or protein hydrolysates capable of giving hydrogen bonds associated with hyaluronic acid or its salts, and to which natural bioflavonoids and antioxidants can be incorporated, also preferably comprise vitamin C.
- the vitamin C used can be in its acid or ascorbic acid form; or in the form of acid salts, such as sodium ascorbate or calcium ascorbate.
- B group vitamins such as vitamins B1 , B2, B6 and B5, as well as any pharmaceutical quality flavouring or flavour enhancer, is also contemplated in order to provide the compositions with improved organoleptic properties.
- liposoluble vitamins vitamins A, D, E
- antiradical agent coenzyme Q10 can also be added.
- compositions can contain mineral salts, such as magnesium carbonate.
- mineral salts such as magnesium carbonate.
- Other mineral salts of calcium, magnesium, sodium, potassium, selenium, copper, zinc, molybdenum, etc. can be added, the intake of these types of compounds thus being modulated according to the requirements or deficiencies of the mammals to which the compositions are to be administered.
- Hyaluronic acid can be used in the form of acid or also in the form of its salts, preferably the sodium salt, according to availability.
- the natural bioflavonoids used comprise at least one of the following compounds: quercetin, naringin, luteolin, apigenin, genistein and hesperidin, in different proportions according to the plant source of origin.
- compositions according to the invention can contain plant extracts or products of animal origin, traditionally used to alleviate functional difficulties due to articular cartilage disorders.
- glucosamine sulphate or chondroitin sulphate which are also widely used for dysfunctions derived from cartilage problems, can be added to said compositions.
- compositions and/or functional foods and/or food supplements indicated above allow, as is deduced from the previous test, increasing the rate of action with regard to the improvement of the functional capacity and/or the quality of life of people or animals that are physically or socially impaired due to articular cartilage disorders.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Animal Husbandry (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Birds (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne une composition destiné à être administrée par voie orale, comprenant un hydrolysat enzymatique de collagène ou d'autres types de polymères ou d'hydrolysats protéiques permettant d'obtenir des liaison hydrogène avec l'acide hyaluronique sous forme d'acide ou d'un de ses sels, pouvant également comprendre des bioflavonoïdes et des antioxydants naturels. La composition est utilisée pour la préparation d'aliments fonctionnels et de compléments alimentaires destinés à améliorer la capacité fonctionnelle et/ou la qualité de vie d'un mammifère souffrant de difficultés fonctionnelles liées à des affections du cartilage articulaire.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200701716A ES2319049B1 (es) | 2007-06-15 | 2007-06-15 | Composicion que comprende hidrolizado de colageno y acido hialuronico para la mejora de dificultades funcionales consecutivas a alteraciones de los cartilagos articulares. |
ESP200701716 | 2007-06-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008152015A1 true WO2008152015A1 (fr) | 2008-12-18 |
Family
ID=39766672
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2008/057151 WO2008152015A1 (fr) | 2007-06-15 | 2008-06-09 | Composition destinée à atténuer les difficultés fonctionnelles liées aux affections du cartilage articulaire |
Country Status (2)
Country | Link |
---|---|
ES (1) | ES2319049B1 (fr) |
WO (1) | WO2008152015A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20111925A1 (it) * | 2011-10-25 | 2013-04-26 | Apharm Srl | Composizioni a base di acido ialuronico e fibre naturali per uso orale atte ad incrementare l'attivita' peristaltica intestinale. |
DE102017006532A1 (de) * | 2017-07-11 | 2019-01-17 | Carlo Bermes | Arzneimittel und Getränk zur Verbesserung von Gelenk- und Knochenleiden |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6211143B1 (en) * | 1998-03-25 | 2001-04-03 | Masterfarm S.L. | Preparation and method for increasing cartilaginous mass of joints in a mammal |
US20020068718A1 (en) * | 2000-10-03 | 2002-06-06 | Pierce Scott W. | Chondroprotective/restorative compositions and methods of use thereof |
US6476005B1 (en) * | 1998-03-24 | 2002-11-05 | George D. Petito | Oral and injectable nutritional composition |
US20020173484A1 (en) * | 2001-05-18 | 2002-11-21 | Harry Leneau | Ingestion of hyaluronic acid for improved joint function and health |
US20030069171A1 (en) * | 1998-03-24 | 2003-04-10 | Petito George D. | Nutritional composition for the treatment of connective tissue |
WO2003034993A2 (fr) * | 2001-10-23 | 2003-05-01 | Petito George D | Composition et procede de croissance, protection et reparation de tissus et cellules |
US20050084518A1 (en) * | 2003-10-20 | 2005-04-21 | Medicaraise | Health food containing hyaluronic acid and dermatan sulfate |
WO2006116452A1 (fr) * | 2005-04-22 | 2006-11-02 | Molecular Regenix, Llc | Composition nutritionnelle comprenant de l'acide hyaluronique et une superoxyde dismutase et procédés de fabrication et d'utilisation de celle-ci |
US20070155666A1 (en) * | 2001-01-24 | 2007-07-05 | Ahmad Alkayali | Canine and equine collagen joint health supplement |
WO2007090504A1 (fr) * | 2006-02-10 | 2007-08-16 | Masterfam, S.L. | Collagene hydrolyse et ses utilisations |
WO2007122179A1 (fr) * | 2006-04-21 | 2007-11-01 | Diana Naturals | Hydrolysat de cartilage avien, procédé de préparation et utilisation |
-
2007
- 2007-06-15 ES ES200701716A patent/ES2319049B1/es active Active
-
2008
- 2008-06-09 WO PCT/EP2008/057151 patent/WO2008152015A1/fr active Application Filing
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6476005B1 (en) * | 1998-03-24 | 2002-11-05 | George D. Petito | Oral and injectable nutritional composition |
US20030069171A1 (en) * | 1998-03-24 | 2003-04-10 | Petito George D. | Nutritional composition for the treatment of connective tissue |
US6211143B1 (en) * | 1998-03-25 | 2001-04-03 | Masterfarm S.L. | Preparation and method for increasing cartilaginous mass of joints in a mammal |
US20020068718A1 (en) * | 2000-10-03 | 2002-06-06 | Pierce Scott W. | Chondroprotective/restorative compositions and methods of use thereof |
US20070155666A1 (en) * | 2001-01-24 | 2007-07-05 | Ahmad Alkayali | Canine and equine collagen joint health supplement |
US20020173484A1 (en) * | 2001-05-18 | 2002-11-21 | Harry Leneau | Ingestion of hyaluronic acid for improved joint function and health |
WO2003034993A2 (fr) * | 2001-10-23 | 2003-05-01 | Petito George D | Composition et procede de croissance, protection et reparation de tissus et cellules |
US20050084518A1 (en) * | 2003-10-20 | 2005-04-21 | Medicaraise | Health food containing hyaluronic acid and dermatan sulfate |
WO2006116452A1 (fr) * | 2005-04-22 | 2006-11-02 | Molecular Regenix, Llc | Composition nutritionnelle comprenant de l'acide hyaluronique et une superoxyde dismutase et procédés de fabrication et d'utilisation de celle-ci |
WO2007090504A1 (fr) * | 2006-02-10 | 2007-08-16 | Masterfam, S.L. | Collagene hydrolyse et ses utilisations |
WO2007122179A1 (fr) * | 2006-04-21 | 2007-11-01 | Diana Naturals | Hydrolysat de cartilage avien, procédé de préparation et utilisation |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20111925A1 (it) * | 2011-10-25 | 2013-04-26 | Apharm Srl | Composizioni a base di acido ialuronico e fibre naturali per uso orale atte ad incrementare l'attivita' peristaltica intestinale. |
DE102017006532A1 (de) * | 2017-07-11 | 2019-01-17 | Carlo Bermes | Arzneimittel und Getränk zur Verbesserung von Gelenk- und Knochenleiden |
WO2019011911A1 (fr) | 2017-07-11 | 2019-01-17 | Bermes Carlo | Médicament et boisson pour l'amélioration de maladies articulaires et osseuses |
Also Published As
Publication number | Publication date |
---|---|
ES2319049A1 (es) | 2009-05-01 |
ES2319049B1 (es) | 2010-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2999763C (fr) | Compositions de flavonoides et procedes d'utilisation | |
EP2903458B1 (fr) | Méthodes d'amélioration de l'effet de l'egcg sur l'atténuation de la perte musculaire squelettique | |
US20160361291A1 (en) | Methods for increasing skeletal muscle protein synthesis using green tea extract | |
JP2016520050A (ja) | 老化筋肉再生の増強方法 | |
JP2008063321A (ja) | 筋肉老化抑制剤 | |
WO2013148685A1 (fr) | Compositions nutritionnelles à base de protéine de pois | |
US20110160136A1 (en) | Polyphenols for the treatment of cartilage disorders | |
EP2859896A1 (fr) | Compositions pharmaceutiques pour le traitement des troubles musculaires | |
RU2320346C2 (ru) | Применение гесперидина или одного из его производных для изготовления лекарственного средства, предназначенного для стимуляции костеобразования | |
US20090022853A1 (en) | Beverage | |
JP5204578B2 (ja) | 関節痛改善用組成物、関節痛改善剤、あるいは食品 | |
WO2015094767A1 (fr) | Méthodes pour maintenir ou augmenter le poids corporel à l'aide d'extrait de thé vert décaféiné | |
WO2008152015A1 (fr) | Composition destinée à atténuer les difficultés fonctionnelles liées aux affections du cartilage articulaire | |
KR101359859B1 (ko) | 다당류를 함유하는 조성물 | |
US20240009218A1 (en) | Compositions and methods using a combination of oleuropein and quercetin for use in cartilage degeneration | |
TW201936065A (zh) | 腸道屏障功能改善用組成物 | |
JP2010111608A (ja) | 筋損傷抑制剤 | |
JP7457353B2 (ja) | 軟骨細胞への分化促進剤、軟骨細胞の増殖促進剤および軟骨基質産生促進剤 | |
WO2023042902A1 (fr) | Promoteur de différenciation en cellule cartilagineuse, promoteur de propagation de cellules cartilagineuses et promoteur de production de matrice cartilagineuse | |
KR20090064449A (ko) | 신규한 기능식품용 및 약학적 조성물 및 관절 내 연골 분해 또는 연골 손상의 치료, 공동치료 또는 예방을 위한 이의 용도 | |
KR20180055966A (ko) | 참나리 주정 추출물을 유효성분으로 함유하는 관절염의 예방, 개선 또는 치료용 조성물 | |
JP2010095474A (ja) | カルシウム吸収促進組成物及びカルシウム吸収促進飲食物 | |
WO2023222703A1 (fr) | Compositions et méthodes utilisant une combinaison de fisétine et de quercétine à des fins d'utilisation dans la dégénerescence du cartilage | |
WO2023222704A1 (fr) | Compositions et méthodes utilisant une association d'oleuropéine et de fisétine à des fins d'utilisation dans la dégénérescence du cartilage | |
WO2024099885A1 (fr) | Compositions et méthodes utilisant une combinaison d'oleuropéine et de taurine pour une utilisation dans la prévention ou le traitement de troubles articulaires |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08760719 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08760719 Country of ref document: EP Kind code of ref document: A1 |